Gene · 7030
Papers3,398
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,398
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deep proteogenomic characterization of pancreatic solid pseudopapillary neoplasm reveals unique features distinct from other pancreatic tumors. | Biomark Res | 2025 | 41310888 | PubTator, text mining | PubMed |
| A case report: identifying a novel variant in ELOC(TCEB1)-mutant renal cell carcinoma. | Front Oncol | 2025 | 41306531 | PubTator, text mining | PubMed |
| MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma. | Cell Rep | 2025 | 41275493 | PubTator, text mining | PubMed |
| A cellular epithelioid hemangioma of the liver harboring a novel FOS::BCAR3 fusion gene. | Virchows Arch | 2025 | 41251743 | PubTator, text mining | PubMed |
| TFE3-rearranged and TFEB-altered renal cell carcinoma: from classification to real-life. Insights from a national Italian survey. | Pathologica | 2025 | 41243505 | PubTator, text mining | PubMed |
| Xanthomatous giant cell renal cell carcinoma: clinicopathologic and molecular characterization of 2 additional cases with biallelic TSC2 mutations. | Am J Clin Pathol | 2025 | 41237373 | PubTator, text mining | PubMed |
| Renal Cell Carcinoma With MED15 Exon 13-TFE3 Exon 6 Fusion Lacks Cystic Architecture. | Pathol Int | 2025 | 41221836 | PubTator, text mining | PubMed |
Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study. | Eur J Cancer | 2025 | 41218239 | PubTator, text mining | PubMed |
| Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma. | Carcinogenesis | 2025 | 41215589 | PubTator, text mining | PubMed |
| Series of renal cell carcinomas with TFE3 overexpression by copy number gains and without TFE3 gene rearrangement. | Virchows Arch | 2025 | 41212280 | PubTator, text mining | PubMed |
| Architecture of the human KICSTOR and GATOR1-KICSTOR complexes. | Nat Struct Mol Biol | 2025 | 41198956 | PubTator, text mining | PubMed |
| Analysis of Clinicopathologic Features and Imaging Findings of TFE3-Rearranged Renal Cell Carcinoma. | Clin Genitourin Cancer | 2025 | 41192013 | PubTator, text mining | PubMed |
| Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching. | World J Urol | 2025 | 41171468 | PubTator, text mining | PubMed |
| TFE3 fusion proteins promoted the progression of Xp11.2 translocation renal cell carcinoma through post-translational modification of PDL1 by upregulating CCND1/Cyclin D1. | Cell Oncol (Dordr) | 2025 | 41171371 | PubTator, text mining | PubMed |
| Genitourinary mesenchymal neoplasms with tumor-defining genetic alterations: A clinicopathologic and molecular correlative study of 71 cases. | Hum Pathol | 2025 | 41130522 | PubTator, text mining | PubMed |
| MED15-TFE3 rearranged renal cell carcinoma: a subtype of TFE3-rearranged renal cell carcinoma with unique clinicopathologic features and better prognosis. | World J Surg Oncol | 2025 | 41121311 | PubTator, text mining | PubMed |
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38). | J Immunother Cancer | 2025 | 41120126 | PubTator, text mining | PubMed |
| Pulmonary epithelioid haemangioendothelioma: A comprehensive review of clinical and molecular advances. | Clinics (Sao Paulo) | 2025 | 41086575 | PubTator, text mining | PubMed |
| EHE cell cultures are a platform for mechanistic and therapeutic investigation. | Sci Rep | 2025 | 41073554 | PubTator, text mining | PubMed |
| TFE3 immunohistochemistry in renal cell carcinomas: Does the clone really matter? | North Clin Istanb | 2025 | 41059424 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7030/papers?page=9